Harrow Health, Inc. (NASDAQ: HROW) reported fourth‑quarter 2025 revenue of $89.09 million, up 36% year‑over‑year, and a full‑year revenue of $272.3 million, a 36% increase from $166.5 million in 2024. The company posted earnings per share of $0.17 for the quarter, missing consensus estimates of $0.38‑$0.45, but beating the prior year’s Q4 2024 EPS of $0.24.
Revenue exceeded analyst expectations of $88.42‑$91.59 million, driven by a mix shift toward higher‑margin branded products such as VEVYE, IHEEZO, and TRIESENCE. The stronger product mix and robust demand for early‑stage launches offset a temporary inventory shortfall in the ImprimisRx compounding business, which had a modest impact on the quarter’s top line.
The EPS miss was largely attributable to higher operating expenses and cost inflation, which compressed margins. The company’s GAAP net loss for the year was $5.1 million, and debt stood at $243.2 million, underscoring the profitability pressure that contributed to the earnings shortfall.
Management reiterated a 2026 revenue guidance of $350 million to $365 million, below the analyst consensus of $386 million. CEO Mark L. Baum said, "Last year was a defining year for Harrow, with revenue up 36 percent for the year and a record fourth quarter that reflected both accelerating demand and improving operating leverage, especially in terms of generating operating cash flow." He added, "Our key products are still in the early stages of launch, and each is gaining significant commercial traction," and "I have increasing confidence in our ability to accelerate performance through 2026, to remain on track toward our goal of over $250 million in quarterly revenue by the end of 2027."
Shares fell 13.51% in after‑hours trading and 14.31% overnight, reflecting investor concern over the EPS miss and the lower 2026 guidance. The decline was driven by the earnings shortfall, the inventory shortfall in ImprimisRx, the company’s net loss and high debt load, and the perception that the guidance signals a more cautious outlook than analysts had anticipated.
The results highlight a company that is growing revenue but facing profitability challenges. Strong demand for branded products and early‑stage launches support top‑line momentum, yet margin compression, inventory constraints, and significant debt create near‑term headwinds. Management’s confidence in accelerating performance through 2026 is tempered by the need to address cost pressures and inventory issues, while the company’s strategic focus on expanding its branded portfolio and achieving $250 million quarterly revenue by 2027 remains a long‑term objective.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.